1. Home
  2. PROK vs MCHX Comparison

PROK vs MCHX Comparison

Compare PROK & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PROK
  • MCHX
  • Stock Information
  • Founded
  • PROK 2015
  • MCHX 2003
  • Country
  • PROK United States
  • MCHX United States
  • Employees
  • PROK N/A
  • MCHX N/A
  • Industry
  • PROK Biotechnology: Biological Products (No Diagnostic Substances)
  • MCHX Business Services
  • Sector
  • PROK Health Care
  • MCHX Consumer Discretionary
  • Exchange
  • PROK Nasdaq
  • MCHX Nasdaq
  • Market Cap
  • PROK 94.9M
  • MCHX 84.3M
  • IPO Year
  • PROK N/A
  • MCHX 2004
  • Fundamental
  • Price
  • PROK $0.81
  • MCHX $1.62
  • Analyst Decision
  • PROK Buy
  • MCHX
  • Analyst Count
  • PROK 4
  • MCHX 0
  • Target Price
  • PROK $5.00
  • MCHX N/A
  • AVG Volume (30 Days)
  • PROK 796.9K
  • MCHX 25.6K
  • Earning Date
  • PROK 05-12-2025
  • MCHX 05-13-2025
  • Dividend Yield
  • PROK N/A
  • MCHX N/A
  • EPS Growth
  • PROK N/A
  • MCHX N/A
  • EPS
  • PROK N/A
  • MCHX N/A
  • Revenue
  • PROK $306,000.00
  • MCHX $47,951,000.00
  • Revenue This Year
  • PROK N/A
  • MCHX $6.83
  • Revenue Next Year
  • PROK N/A
  • MCHX N/A
  • P/E Ratio
  • PROK N/A
  • MCHX N/A
  • Revenue Growth
  • PROK N/A
  • MCHX N/A
  • 52 Week Low
  • PROK $0.46
  • MCHX $1.23
  • 52 Week High
  • PROK $4.44
  • MCHX $2.40
  • Technical
  • Relative Strength Index (RSI)
  • PROK 49.17
  • MCHX 57.72
  • Support Level
  • PROK $0.94
  • MCHX $1.36
  • Resistance Level
  • PROK $0.87
  • MCHX $1.50
  • Average True Range (ATR)
  • PROK 0.11
  • MCHX 0.13
  • MACD
  • PROK 0.01
  • MCHX 0.04
  • Stochastic Oscillator
  • PROK 39.10
  • MCHX 69.23

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

About MCHX Marchex Inc. Class B

Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.

Share on Social Networks: